Jagsonpal Pharma

Which are the latest news on Jagsonpal Pharma?

Why is Jagsonpal Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Jagsonpal Pharmaceuticals Ltd's stock price is at 241.00, down 1.6 (-0.66%). Despite today's decline, the stock has shown strong performance trends, with significant gains over various periods and increased investor interest.

As of 05-Sep, Jagsonpal Pharmaceuticals Ltd's stock price is currently at 241.00, reflecting a decrease of 1.6 (-0.66%). Despite this decline, the stock has shown positive performance trends over various periods. For instance, over the past week, the stock has increased by 0.46%, while the benchmark Sensex has fallen by 0.97%. In the past month, Jagsonpal Pharmaceuticals has gained 1.84%, contrasting with a 2.44% decline in the Sensex. Year-to-date, the stock has risen significantly by 24.77%, while the Sensex has decreased by 10.21%. <BR><BR>Additionally, the stock has outperformed the benchmark over the last three years with a growth of 44.88% compared to the Sensex's 16.59%, and an impressive 314.80% increase over the past five years against the Sensex's 31.63%. <BR><BR>Today's trading activity indicates that Jagsonpal Pharmaceuticals is performing in line with its sector, and it is trading above its moving averages for 5, 20, 50, 100, and 200 days, suggesting a strong underlying trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 150.64% compared to the 5-day average. This indicates a growing interest in the stock, contributing to its overall positive outlook despite the current minor decline in price. <BR><BR>In summary, while the stock is experiencing a slight drop today, its overall performance metrics and rising investor participation suggest a resilient position in the market.

Who are in the management team of Jagsonpal Pharma?

The management team of Jagsonpal Pharma includes Manish Gupta (Managing Director), Harsha Raghavan (Chairman & Non-Executive Director), and several Independent Directors: Debasis Bikash Nandy, Radhika Dudhat, and Pallavi Dinodia, along with Prithipal Singh Kochhar (Non-Executive Director) and Abhishek Joshi (Company Secretary & Compliance Officer).

The management team of Jagsonpal Pharma includes the following individuals:<BR><BR>1. **Manish Gupta** - Managing Director<BR>2. **Harsha Raghavan** - Chairman & Non-Executive Director<BR>3. **Debasis Bikash Nandy** - Independent Director<BR>4. **Radhika Dudhat** - Independent Director<BR>5. **Pallavi Dinodia** - Independent Director<BR>6. **Prithipal Singh Kochhar** - Non-Executive Director<BR>7. **Abhishek Joshi** - Company Secretary & Compliance Officer<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does Jagsonpal Pharma do?

Jagsonpal Pharmaceuticals Ltd manufactures and markets bulk drugs and pharmaceuticals, classified as a Micro Cap company with a market cap of INR 1,587 Cr. For the quarter ending June 2026, it reported net sales of 82 Cr and a net profit of 13 Cr.

Overview: <BR>Jagsonpal Pharmaceuticals Ltd is engaged in the manufacture and marketing of bulk drugs and pharmaceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in August 1978 by Rajpal Singh Kochhar, Jagsonpal Pharmaceuticals has maintained its focus on pharmaceuticals and reported net sales and profit for the quarter ending June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 82 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 13 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,587 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.05% <BR>Debt-Equity: -0.59 <BR>Return on Equity: 18.60% <BR>Price to Book: 6.29<BR><BR>Contact Details: <BR>Address: T-210 J, Shahpur Jat New Delhi New Delhi : 110049 <BR>Tel: 91-011-46181100/46109900 <BR>Email: nandita.singh@jagsonpal.com <BR>Website: http://www.jagsonpal.com

Who are the peers of the Jagsonpal Pharma?

Jagsonpal Pharma's peers include Shukra Pharma, Hester Bios, Syncom Formulations, NGL Fine Chemicals, Amrutanjan Health, Fermenta Biotec, Sigachi Industries, Lincoln Pharma, and Accent Microcell. NGL Fine Chem leads with an 88.02% 1-year return, while Jagsonpal Pharma has a 2.95% return, higher than Amrutanjan Health's -26.26%.

Peers: The peers of Jagsonpal Pharma are Shukra Pharma., Hester Bios, Syncom Formul., NGL Fine Chem, Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., Lincoln Pharma., and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt and Accent Microcell, while Average management risk is found at Shukra Pharma., Hester Bios, Syncom Formul., NGL Fine Chem, Fermenta Biotec., Sigachi Indust., Lincoln Pharma., and Sakar Healthcare. Growth is rated as Excellent for Shukra Pharma., Good for Accent Microcell, and Below Average for Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., Lincoln Pharma., and the rest. Capital Structure is rated as Excellent for Shukra Pharma., NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, Sigachi Indust., Lincoln Pharma., and Accent Microcell, while Below Average is noted for Hester Bios and Fermenta Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is NGL Fine Chem at 88.02%, while Amrutanjan Healt has the lowest at -26.26%. Jagsonpal Pharma's 1-year return of 2.95% is significantly lower than NGL Fine Chem's and higher than Amrutanjan Healt's. Additionally, Amrutanjan Healt and Fermenta Biotec. have negative six-month returns.

How big is Jagsonpal Pharma?

As of 31st August, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,587.00 Cr, with recent net sales of 293.85 Cr and a net profit of 45.47 Cr.

As of 31st August, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,587.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 293.85 Cr and a Net Profit of 45.47 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 239.95 Cr and Total Assets of 278.26 Cr.

Are Jagsonpal Pharmaceuticals Ltd latest results good or bad?

Jagsonpal Pharmaceuticals Ltd reported strong Q1 FY27 results, with a net profit increase of 50.56% to ₹13.19 crores and revenue growth of 28.08% to ₹82.23 crores. While the performance is positive, the stock's premium valuation may warrant caution for potential investors.

Jagsonpal Pharmaceuticals Ltd has reported strong results for Q1 FY27, indicating a positive performance. The company achieved a net profit of ₹13.19 crores, which is a significant increase of 50.56% compared to the previous quarter. Additionally, revenue grew by 28.08% sequentially to ₹82.23 crores, and year-on-year revenue growth was recorded at 8.76%. <BR><BR>The operating margin improved to 20.97%, reflecting better operational efficiency and a favorable product mix. The return on equity (ROE) stands at a solid 17.66%, showcasing effective management in generating returns for shareholders.<BR><BR>Overall, the results suggest that Jagsonpal Pharmaceuticals is on a positive trajectory, with strong financial metrics and operational improvements. However, it's worth noting that while the recent performance is commendable, the stock has been trading at a premium valuation, which may warrant caution for potential investors.

Should I buy, sell or hold Jagsonpal Pharmaceuticals Ltd?

When is the next results date for Jagsonpal Pharmaceuticals Ltd?

The next results date for Jagsonpal Pharmaceuticals Ltd is July 29, 2026.

The next results date for Jagsonpal Pharmaceuticals Ltd is scheduled for July 29, 2026.

Is Jagsonpal Pharma technically bullish or bearish?

As of December 1, 2025, Jagsonpal Pharma's trend is mildly bearish due to bearish momentum indicated by the weekly MACD and KST, despite some mixed signals from Bollinger Bands and Dow Theory.

As of 1 December 2025, the technical trend for Jagsonpal Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a mildly bearish outlook. The weekly Bollinger Bands suggest a mildly bearish trend, contrasting with the monthly Bollinger Bands which are bullish. The Dow Theory shows a mildly bullish signal on the weekly timeframe, but overall, the lack of strong bullish signals in the MACD and RSI, combined with the mixed indicators, supports the mildly bearish stance.

How has been the historical performance of Jagsonpal Pharma?

Jagsonpal Pharma has shown significant financial growth, with net sales increasing from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, and profit after tax rising from 7.22 crore to 55.36 crore during the same period. The company has also improved its operating profit margin from 5.38% to 19.0%.

Answer:<BR>The historical performance of Jagsonpal Pharma shows a significant growth trajectory in its financial metrics over the years.<BR><BR>Breakdown:<BR>Jagsonpal Pharma's net sales increased from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 166.83 crore in Mar'19 to 268.72 crore in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 crore in Mar'20 to 59.26 crore in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 crore in Mar'19 to 69.86 crore in Mar'25, while profit after tax rose from 7.22 crore to 55.36 crore, indicating a robust increase in profitability. The company's total assets grew from 146.95 crore in Mar'20 to 278.26 crore in Mar'25, with total liabilities also increasing from 146.95 crore to 278.26 crore. Cash flow from operating activities improved significantly, reaching 55.00 crore in Mar'25 compared to 11.00 crore in Mar'20. Overall, Jagsonpal Pharma has demonstrated strong financial growth and improved profitability over the years.

Is Jagsonpal Pharma overvalued or undervalued?

As of June 5, 2024, Jagsonpal Pharma is considered very expensive and overvalued with a PE ratio of 39.87, significantly higher than its peers, indicating that investors may be paying too much for its future growth potential despite a strong recent performance.

As of 5 June 2024, Jagsonpal Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 39.87, a Price to Book Value of 6.45, and an EV to EBITDA of 27.96, all of which are elevated compared to industry norms.<BR><BR>In comparison to peers, Jagsonpal Pharma's PE ratio is higher than Sun Pharma's 35.25 and significantly exceeds Cipla's 22.99, highlighting its premium valuation. While the company has shown strong returns over the past year, with a 71.87% increase compared to the Sensex's 7.58%, the current valuation metrics suggest that investors may be paying too much for future growth potential.

Who are the top shareholders of the Jagsonpal Pharma?

The top shareholders of Jagsonpal Pharma include Aresko Progressive Private Limited with 20.08%, followed by individual investors holding 20.94%, and Manish Gupta as the highest public shareholder at 2.49%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Jagsonpal Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Aresko Progressive Private Limited, which owns 20.08% of the company. Additionally, there are 11 Foreign Institutional Investors (FIIs) holding a combined 2.1% of the shares. The highest public shareholder is Manish Gupta, with a holding of 2.49%. Individual investors collectively hold 20.94% of the shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Has Jagsonpal Pharma declared dividend?

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend, amounting to ₹5 per share, with an ex-date of September 6, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite a recent short-term decline.

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.86%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.44%, with a dividend return of 0%, resulting in a total return of -15.44%.<BR><BR>Over the past year, the price return was 78.07%, the dividend return was 3.72%, leading to a total return of 81.79%.<BR><BR>In the last 2 years, the price return stood at 57.23%, with a dividend return of 3.24%, culminating in a total return of 60.47%.<BR><BR>For the 3-year period, the price return was 93.26%, the dividend return was 4.31%, resulting in a total return of 97.57%.<BR><BR>Over the past 4 years, the price return reached 361.1%, with a dividend return of 15.53%, leading to a total return of 376.63%.<BR><BR>In the 5-year period, the price return was an impressive 1943.42%, with a dividend return of 67.57%, resulting in a total return of 2010.99%.<BR><BR>Overall, Jagsonpal Pharmaceuticals Ltd has declared a significant dividend while demonstrating strong total returns over various periods, particularly notable in the longer-term performance. The company appears to be a solid investment with a consistent track record of returns, despite a recent decline in the short term.